GLP-1s for Sleep Apnea: How Zepbound Could Replace Your CPAP

If you hate your CPAP machine, this article is for you. In December 2024, Zepbound became the first medication ever approved by the FDA to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. For the roughly 30 million Americans with sleep apnea, this is a genuine game-changer — and it could transform how your insurance views GLP-1 treatment.

What Is Obstructive Sleep Apnea?

Obstructive sleep apnea is a condition where the airway partially or completely collapses during sleep, causing repeated breathing interruptions. These interruptions — called apnea events — can happen dozens or even hundreds of times per night, each one briefly waking your brain (often without you realizing it) and preventing deep, restorative sleep.

Severity is measured by the Apnea-Hypopnea Index (AHI) — the number of breathing interruptions per hour of sleep. Mild OSA: 5-14 events/hour. Moderate: 15-29. Severe: 30 or more. Until Zepbound, the primary treatments were CPAP machines (which work but have notoriously poor adherence — roughly 50% of patients stop using them), dental appliances, and surgery.

The link to obesity is direct: excess weight around the neck and upper airway narrows the breathing passage. Roughly 60-90% of people with OSA have obesity, and for many, treating the obesity is the most effective way to treat the sleep apnea.

The SURMOUNT-OSA Trials: Landmark Results

The FDA approval was based on two Phase 3 trials: SURMOUNT-OSA 1 (patients not using CPAP) and SURMOUNT-OSA 2 (patients using CPAP who wanted better results). Results were published in the New England Journal of Medicine in 2024.

To put those numbers in perspective: a 23.8 events/hour AHI reduction can take someone from waking up 40 times per hour to fewer than 15 — from severe to moderate or mild. For many trial participants, sleep apnea effectively resolved entirely (AHI below 5).

How It Works: More Than Just Weight Loss

The weight loss component is obvious — reducing fat deposits around the airway physically opens the breathing passage. But researchers believe GLP-1 medications may also have direct effects on upper airway muscle tone. GLP-1 receptors exist in brainstem regions that control respiratory function, suggesting the drugs may help maintain airway patency during sleep independent of weight changes.

The SURMOUNT-OSA data supports this: AHI improvements were seen relatively early in treatment, before maximum weight loss was achieved, suggesting a mechanism beyond weight reduction alone.

What This Means for Your Life

If you're one of the millions who have abandoned a CPAP machine (or never started one), this could be transformative. Consider the quality-of-life improvements patients reported:

• Better sleep — actually reaching deep, restorative sleep stages
• No more CPAP — no mask, no hose, no machine noise, no dry mouth
• Easier travel — no carrying medical equipment through airports
• Improved intimacy — CPAP is a notorious relationship disruptor
• Daytime energy — reduced sleepiness, better cognitive function
• Cardiovascular protection — untreated OSA is a major risk factor for heart disease, stroke, and arrhythmia

The Insurance Coverage Opportunity

This is the practical win that many patients overlook. If your insurance won't cover GLP-1s for weight loss, an OSA diagnosis creates an alternative pathway. Since Zepbound is now FDA-approved for obstructive sleep apnea, your provider can prescribe tirzepatide specifically for that indication.

The process: get a sleep study (polysomnography or home sleep test), receive a formal OSA diagnosis with severity classification, and submit a prior authorization request specifically citing the OSA indication. This is a different coverage pathway than weight management — and many plans that exclude weight loss drugs cover approved treatments for diagnosed sleep disorders.

Zepbound vs. CPAP: Not Either/Or

It's important to note that Zepbound may not completely replace CPAP for everyone. The SURMOUNT-OSA 2 trial specifically studied patients who were using CPAP — the drug improved their outcomes further, suggesting combination therapy may be optimal for severe cases.

For mild-to-moderate OSA in people with obesity, Zepbound alone may be sufficient. For severe cases, it may reduce the severity enough that CPAP becomes more comfortable (lower pressure settings) or potentially unnecessary. Your sleep medicine provider should make this determination based on follow-up sleep testing after treatment.

What About Semaglutide for Sleep Apnea?

Currently, only Zepbound (tirzepatide) has the FDA-approved OSA indication. Wegovy (semaglutide) does not. However, given that any GLP-1-induced weight loss will reduce OSA severity, many providers prescribe semaglutide for patients with both obesity and OSA, noting the weight management indication while recognizing the sleep benefits.

If your priority is specifically treating sleep apnea with an FDA-approved medication, Zepbound is the current choice. If your insurance covers semaglutide for weight management and you also have OSA, the sleep benefits will come alongside the weight loss.

The Bottom Line

Zepbound's approval for sleep apnea marks another milestone in the repositioning of GLP-1s from “weight loss drugs” to comprehensive metabolic health treatments. For the millions of Americans suffering with OSA — and the millions more who've given up on their CPAP — this offers a new pathway to better sleep, better health, and potentially better insurance coverage.

Combined with the cardiovascular protection (SELECT trial), kidney protection (FLOW trial), liver disease treatment (MASH approval), and the broad metabolic benefits, GLP-1 therapy is building the strongest evidence base of any drug class in recent memory.